Skip to main content
. Author manuscript; available in PMC: 2013 Aug 14.
Published in final edited form as: Clin Cancer Res. 2012 Jun 18;18(16):4465–4472. doi: 10.1158/1078-0432.CCR-12-0286

Table 3.

Multivariate analysis of prognostic variables

DFS
OS
Variable Comparison HR (95% CI) P HR (95% CI) P
Subtype Basal vs. Luminal A 1.57 (0.75–3.29) 0.02 2.19 (0.91–5.26) 0.02
Her2+ vs. Luminal A 2.25 (1.29–3.90) 2.74 (1.39–5.40)
Luminal B vs. Luminal A 1.98 (1.16–3.39) 2.40 (1.25–4.63)
Treatment Tamoxifen vs. placebo 0.58 (0.41–0.82) 0.002 0.68 (0.45–1.02) 0.06
ER Positive vs. negative 0.82 (0.53–1.28) 0.38 0.58 (0.35–0.97) 0.04
Nodal status 1–3 vs. negative 1.97 (1.20–3.22) 0.02 1.61 (0.92–2.81) 0.17
>3 vs. negative 1.97 (1.12–3.48) 1.78 (0.94–3.37)
Tumor size T stage 1 vs. >1 0.64 (0.44–0.92) 0.02 0.62 (0.40–0.96) 0.03
Tumor grade 1 vs. 2 vs. 3 0.96 (0.71–1.31) 0.81 0.83 (0.58–1.19) 0.30